Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal ranibizumab as early treatment for macular edema from retinal vein occlusion
ChiCTR-OIC-16009509Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jan 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in Vein occlusion (RVO), sponsored by The Second Xiangya Hospital. Primary endpoints: visual acuity and macular edema. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
ranibizumab
03
Conditions
Vein occlusion (RVO)
Beyond the preview
Go deeper on ChiCTR-OIC-16009509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16009509.